UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

________________________________________________________

FORM 8-K

________________________________________________________

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~August~~November 263, 2025

________________________________________________________

Precision BioSciences, Inc.

(Exact name of Registrant as Specified in Its Charter)

________________________________________________________


Delaware	001-38841	20-4206017
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

302 East Pettigrew St. Suite A-100
Durham, North Carolina		27701
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s Telephone Number, Including Area Code: 919 314-5512

(Former Name or Former Address, if Changed Since Last Report)

________________________________________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


☐			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading
Symbol(s)

Name of each exchange on which registered

Common Stock, par value $0.000005 per share

DTIL

The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 52.02 ~~Departure~~Results of ~~Directors~~Operations orand ~~Certain~~Financial ~~Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers~~Condition.

On ~~August~~November 263, 2025, Precision BioSciences, Inc. (the “Company”) ~~entered~~issued ~~into~~a ~~amended~~press ~~and~~release ~~restated~~announcing ~~employment agreements to help retain each of~~ its ~~Section~~financial 16results ~~officers:~~for ~~Michael Amoroso,~~ the ~~Company’s~~quarter ~~President~~ended ~~and~~September ~~Chief Executive Officer; Alex Kelly~~30, ~~the Company’s Chief Financial Officer; Dario Scimeca, the Company’s General Counsel and Secretary; and Jeff Smith, the Company’s Chief Research Officer~~2025. The ~~employment~~full ~~agreements~~text ~~are~~of ~~substantively similar to their prior employment agreements, except that they reflect such executive’s current annual base salary and target bonus amounts, provide for~~ the ~~payment~~press ofrelease ~~existing~~is ~~cash~~furnished ~~severance in a lump sum, include provisions regarding termination without cause in connection with a “change in control” or a “restructuring event” (each~~ as ~~defined~~Exhibit ~~in the respective employment agreements), and provide for a payment to cover potential additional expenses~~99.1 ~~The amended employment agreements also include a requirement~~ to ~~fund~~this ~~the~~Current ~~cash~~Report ~~severance~~on ~~and~~Form ~~expenses~~8-K ~~in an escrow account. As a result, the Company entered into escrow arrangements with JPMorgan Chase Bank, N.A.~~ and ~~the~~is ~~executives~~incorporated ~~with~~herein ~~respect~~by ~~to the funded amounts~~reference. ~~Interest earned from the escrow account accrues to Precision BioSciences and any unused funds return to Precision BioSciences.~~

Item 9.01 Financial Statements and Exhibits.

(d)Exhibits


Exhibit No.						Description

99.1						Press release of Precision BioSciences, Inc. dated November 3 , 2025.

104						Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			PRECISION BIOSCIENCES, INC.
Date:	~~September~~November 23, 2025	By:	/s/ ~~Dario~~John ~~Scimeca~~Alexander Kelly
			Dario ScimecaGeneral Counsel
			John Alexander KellyChief Financial Officer

Filing Compare · PRECISION BIOSCIENCES INC